(Q41935356)

14 October 2017

title

Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells? (English)

1 reference

14 October 2017

main subject

multiple drug resistance

1 reference

1 reference

Kayyali R

1

1 reference

14 October 2017

Marriott C

series ordinal

2

1 reference

14 October 2017

Wiseman H

series ordinal

3

1 reference

14 October 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

14 October 2017

1 reference

14 October 2017

volume

344

1 reference

14 October 2017

issue

2-3

1 reference

14 October 2017

page(s)

221-224

1 reference

Overview from the International Conference on Long-Term Tamoxifen Therapy for Breast Cancer

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Results of the Cancer Research Campaign Adjuvant Trial for Perioperative Cyclophosphamide and Long-Term Tamoxifen in Early Breast Cancer reported at the tenth year of follow-up. Cancer Research Campaign Breast Cancer Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Breast cancer chemoprevention. Tamoxifen: current issues and future prospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

21 January 2018

How safe is tamoxifen?

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anti-cancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

The case for clinical trials of tamoxifen for prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2F0014-5793%2894%2900378-5

10.1016/0014-5793(94)00378-5

21 January 2018

Identifiers

DOI

1 reference

14 October 2017

1 reference